Would ITCs in a single axillary node push you towards recommending adjuvant chemotherapy for a young woman with a T1a (<2mm) triple negative breast cancer?

Topics: Breast Cancer • Medical Oncology • NCI-CCC Tumor Board Question • Triple negative • Ohio State University • NCI-CCC Breast Tumor Board Question

Patient underwent an axillary dissection with ITCs in 1/23 nodes.

Answer from: Medical Oncologist at Academic Institution

The impact of ITCs in axillary nodes has been a subject of debate. de Boer et al., PMID 19675329 reported that adjuvant therapy reduced the risk of subsequent events in those with isolated tumor cells compared to those who did not get adjuvant therapy (hazard ratio 0.66, CI 0.46-0.95). However, a tu...

Related Questions